Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
- PMID:32946782
- PMCID: PMC7593816
- DOI: 10.1016/j.cell.2020.08.024
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
Abstract
Hallucinogens like lysergic acid diethylamide (LSD), psilocybin, and substituted N-benzyl phenylalkylamines are widely used recreationally with psilocybin being considered as a therapeutic for many neuropsychiatric disorders including depression, anxiety, and substance abuse. How psychedelics mediate their actions-both therapeutic and hallucinogenic-are not understood, although activation of the 5-HT2A serotonin receptor (HTR2A) is key. To gain molecular insights into psychedelic actions, we determined the active-state structure of HTR2A bound to 25-CN-NBOH-a prototypical hallucinogen-in complex with an engineered Gαq heterotrimer by cryoelectron microscopy (cryo-EM). We also obtained the X-ray crystal structures of HTR2A complexed with the arrestin-biased ligand LSD or the inverse agonist methiothepin. Comparisons of these structures reveal determinants responsible for HTR2A-Gαq protein interactions as well as the conformational rearrangements involved in active-state transitions. Given the potential therapeutic actions of hallucinogens, these findings could accelerate the discovery of more selective drugs for the treatment of a variety of neuropsychiatric disorders.
Keywords: GPCR; LSD; psychedelic; sertotonin receptor; signal transduction; structural biology.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests The authors declare no competing interests.
Figures







Similar articles
- Structure-based discovery of nonhallucinogenic psychedelic analogs.Cao D, Yu J, Wang H, Luo Z, Liu X, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J, Wang S.Cao D, et al.Science. 2022 Jan 28;375(6579):403-411. doi: 10.1126/science.abl8615. Epub 2022 Jan 27.Science. 2022.PMID:35084960
- Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD.Cao C, Barros-Álvarez X, Zhang S, Kim K, Dämgen MA, Panova O, Suomivuori CM, Fay JF, Zhong X, Krumm BE, Gumpper RH, Seven AB, Robertson MJ, Krogan NJ, Hüttenhain R, Nichols DE, Dror RO, Skiniotis G, Roth BL.Cao C, et al.Neuron. 2022 Oct 5;110(19):3154-3167.e7. doi: 10.1016/j.neuron.2022.08.006. Epub 2022 Sep 9.Neuron. 2022.PMID:36087581Free PMC article.
- Structural pharmacology and therapeutic potential of 5-methoxytryptamines.Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D.Warren AL, et al.Nature. 2024 Jun;630(8015):237-246. doi: 10.1038/s41586-024-07403-2. Epub 2024 May 8.Nature. 2024.PMID:38720072Free PMC article.
- Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways.López-Giménez JF, González-Maeso J.López-Giménez JF, et al.Curr Top Behav Neurosci. 2018;36:45-73. doi: 10.1007/7854_2017_478.Curr Top Behav Neurosci. 2018.PMID:28677096Free PMC article.Review.
- The promises and perils of psychedelic pharmacology for psychiatry.McClure-Begley TD, Roth BL.McClure-Begley TD, et al.Nat Rev Drug Discov. 2022 Jun;21(6):463-473. doi: 10.1038/s41573-022-00421-7. Epub 2022 Mar 17.Nat Rev Drug Discov. 2022.PMID:35301459Review.
Cited by
- Structural determinants of cholesterol recognition in helical integral membrane proteins.Marlow B, Kuenze G, Li B, Sanders CR, Meiler J.Marlow B, et al.Biophys J. 2021 May 4;120(9):1592-1604. doi: 10.1016/j.bpj.2021.02.028. Epub 2021 Feb 26.Biophys J. 2021.PMID:33640379Free PMC article.
- Synthetic surprise as the foundation of the psychedelic experience.De Filippo R, Schmitz D.De Filippo R, et al.Neurosci Biobehav Rev. 2024 Feb;157:105538. doi: 10.1016/j.neubiorev.2024.105538. Epub 2024 Jan 12.Neurosci Biobehav Rev. 2024.PMID:38220035Free PMC article.Review.
- The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.Egyed A, Kiss DJ, Keserű GM.Egyed A, et al.Front Pharmacol. 2022 Mar 9;13:847788. doi: 10.3389/fphar.2022.847788. eCollection 2022.Front Pharmacol. 2022.PMID:35355719Free PMC article.Review.
- G Protein-coupled Receptor (GPCR) Reconstitution and Labeling for Solution Nuclear Magnetic Resonance (NMR) Studies of the Structural Basis of Transmembrane Signaling.Ge H, Wang H, Pan B, Feng D, Guo C, Yang L, Liu D, Wüthrich K.Ge H, et al.Molecules. 2022 Apr 20;27(9):2658. doi: 10.3390/molecules27092658.Molecules. 2022.PMID:35566006Free PMC article.Review.
- μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.Salinsky LM, Merritt CR, Zamora JC, Giacomini JL, Anastasio NC, Cunningham KA.Salinsky LM, et al.Front Pharmacol. 2023 Oct 11;14:1239159. doi: 10.3389/fphar.2023.1239159. eCollection 2023.Front Pharmacol. 2023.PMID:37886127Free PMC article.Review.
References
- Bogenschutz MP (2013). Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin. Curr. Drug Abuse Rev. 6, 17–29. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources